NCT00493532No Longer Available不适用
An Open Label Study to Evaluate the Effect on Bone Mineral Density, and the Safety, of Quarterly Intravenous Bonviva in Patients With Post-menopausal Osteoporosis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
研究概览
简要总结
This single arm study will assess the efficacy and safety of quarterly intravenous Bonviva in women with post-menopausal osteoporosis. All patients will receive Bonviva 3mg i.v. every 3 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 100 individuals.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- — 至 80 Years（Child, Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •post-menopausal women with osteoporosis;
- •<=80 years of age;
- •naive to oral bisphosphonates, or have discontinued daily and/or weekly bisphosphonate treatment for >1 year.
排除标准
- •metabolic bone disease other than post-menopausal osteoporosis;
- •treatment with other drugs affecting bone metabolism within last 6 months;
- •previous or current malignant disease (except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer).
研究者
相似试验
已完成
3 期
A Study of Intravenous Mircera in Participants With Chronic Renal Anemia Who Are on DialysisAnemiaNCT00660023Hoffmann-La Roche124
已完成
2 期
A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Malignant Bone Disease.Pain; Bone Neoplasms; Neoplasm MetastasisNCT00502736Hoffmann-La Roche13
已完成
3 期
Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the KneeOsteoarthritis, KneeNCT03529942Pacira Pharmaceuticals, Inc129
已完成
不适用
Study Evaluating the Efficacy and Safety of BENEV Exosome Regenerative Complex+ for Self-perceived Thinning HairThinning HairNCT06571799Ablon Skin Institute Research Center30
已完成
3 期
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyJuvenile Absence EpilepsyChildhood Absence EpilepsyNCT05109234UCB Biopharma SRL84